Orchid Pharma gets EIR report from FDA

Orchid Pharma has received Establishment Inspection Report (EIR) from the FDA based on the successful inspection closure for its formulations plant in Tamil Nadu

id-10098828

The facility was inspected by US health regulator in the month of May 2015

Orchid Pharma has informed BSE that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, Sriperumbudur, Kancheepuram District, India.

The facility was inspected by US health regulator in the month of May 2015.

Orchid Pharma is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.

 

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X